Form 4: Integra LifeSciences Holdings Corp: Executive Chairman Stuart Essig Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Stuart Essig, Executive Chairman of Integra LifeSciences, reports acquisition of shares through non-open market transactions.
Summary
- On May 9, 2024, Stuart Essig, the Executive Chairman of the Board at Integra LifeSciences Holdings Corp, reported changes in beneficial ownership of the company's common stock.
- Essig acquired 3,163 shares and 10,672 shares of common stock through transactions not conducted on the open market.
- Following these transactions, Essig directly owns 935,281 shares of Integra LifeSciences.
- Essig also indirectly owns 152,397 shares through a GRAT, 400,000 shares through a GRAT D, and 213,115 shares through a trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions.
Positives
- The increase in share ownership by a key executive could be interpreted positively by investors.
Industry Context
This filing is a routine disclosure related to changes in beneficial ownership by a company insider, as required by the SEC. It provides transparency into the trading activities of key executives.
Stakeholder Impact
- Shareholders may be interested in the trading activity of key executives as an indicator of company performance and confidence.
Key Dates
| Date | Description |
|---|---|
| 05/09/2024 | Date of the reported transactions involving the acquisition of Integra LifeSciences common stock. |
| 05/13/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.